Skip to main content
Erschienen in: Journal of Gastroenterology 11/2015

01.11.2015 | Original Article—Alimentary Tract

Contribution of susceptibility variants at FCGR2A and 13q12 to the risk of relapse among Japanese patients with ulcerative colitis

verfasst von: Kouichi Asano, Motohiro Esaki, Junji Umeno, Atsushi Hirano, Yuji Maehata, Tomohiko Moriyama, Shotaro Nakamura, Takayuki Matsumoto, Takanari Kitazono

Erschienen in: Journal of Gastroenterology | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent genome-wide association studies have identified nearly 100 susceptibility genes for ulcerative colitis (UC). However, the contribution of susceptibility variants for UC to clinical outcome has scarcely been reported. The aim of this study was to investigate whether UC-associated genetic variants confer a risk of clinical relapse.

Methods

One hundred and nine consecutive Japanese subjects with quiescent UC were recruited. Four genetic variants of HLA-DRB1*1502, rs6671847 at FCGR2A, rs17085007 at 13q12, and rs2108225 at SLC26A3 were genotyped by Invader assay. The clinical courses were followed after blood sampling, and the risk of relapse according to these genotypes was calculated by Cox proportional hazard model.

Results

During the mean follow-up period of 35 months (range 1–81 months), 49 of 109 subjects (45 %) relapsed. Carriers of the G allele of rs6671847 showed an increased risk of relapse compared with non-carriers [adjusted hazard ratio (HR), 2.27; 95 % confidence interval (CI), 1.20–4.32; p = 0.01]. Patients with the CT or TT genotypes of rs17085007 also had an increased risk of relapse compared to subjects with the CC genotype (for CT: adjusted HR, 2.16; 95 % CI, 1.10–4.23; p = 0.03; for TT: adjusted HR, 3.25; 95 % CI, 1.18–8.95; p = 0.02). These two risk variants multiplied the risk of relapse by 2.74 times (95 % CI, 1.10–4.23; p = 0.01) in patients with one risk genotype and 5.40 times (95 % CI, 2.06–14.13; p = 0.0006) in patients with both risk genotypes.

Conclusions

Genetic variants of rs6671847 at FCGR2A and rs17085007 at 13q12 conferred a risk of relapse in patients with UC.
Literatur
2.
Zurück zum Zitat Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.CrossRefPubMed Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.CrossRefPubMed
3.
Zurück zum Zitat Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260–6.CrossRefPubMed Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260–6.CrossRefPubMed
4.
Zurück zum Zitat Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–8.CrossRefPubMed Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–8.CrossRefPubMed
5.
Zurück zum Zitat Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481–9.CrossRefPubMed Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481–9.CrossRefPubMed
6.
Zurück zum Zitat Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13–20.CrossRefPubMed Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13–20.CrossRefPubMed
7.
Zurück zum Zitat Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123–8.CrossRefPubMed Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123–8.CrossRefPubMed
8.
Zurück zum Zitat Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207–12.CrossRefPubMed Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207–12.CrossRefPubMed
9.
Zurück zum Zitat Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246–52.PubMedCentralCrossRefPubMed Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246–52.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Arimura Y, Isshiki H, Onodera K, et al. Characteristics of Japanese inflammatory bowel disease susceptibility loci. J Gastroenterol. 2014;49:1217–30.CrossRefPubMed Arimura Y, Isshiki H, Onodera K, et al. Characteristics of Japanese inflammatory bowel disease susceptibility loci. J Gastroenterol. 2014;49:1217–30.CrossRefPubMed
11.
Zurück zum Zitat Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.PubMedCentralCrossRefPubMed Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Beaugerie L, Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol. 2012;18:3806–13.PubMedCentralCrossRefPubMed Beaugerie L, Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol. 2012;18:3806–13.PubMedCentralCrossRefPubMed
13.
14.
Zurück zum Zitat Schachter H, Kirsner JB. Definitions of inflammatory bowel disease of unknown etiology. Gastroenterology. 1975;68:591–600.PubMed Schachter H, Kirsner JB. Definitions of inflammatory bowel disease of unknown etiology. Gastroenterology. 1975;68:591–600.PubMed
15.
Zurück zum Zitat Seo M, Okada M, Maeda K, Oh K. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol. 1998;93:2124–9.CrossRefPubMed Seo M, Okada M, Maeda K, Oh K. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol. 1998;93:2124–9.CrossRefPubMed
16.
Zurück zum Zitat Asano K, Matsushita T, Umeno J, et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. 2009;41:1325–9.CrossRefPubMed Asano K, Matsushita T, Umeno J, et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. 2009;41:1325–9.CrossRefPubMed
17.
Zurück zum Zitat de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet. 2006;38:1166–72.PubMedCentralCrossRefPubMed de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet. 2006;38:1166–72.PubMedCentralCrossRefPubMed
18.
19.
Zurück zum Zitat Zhou B, Fine J, Laird G. Goodness-of-fit test for proportional subdistribution hazards model. Stat Med. 2013;32:3804–11.CrossRefPubMed Zhou B, Fine J, Laird G. Goodness-of-fit test for proportional subdistribution hazards model. Stat Med. 2013;32:3804–11.CrossRefPubMed
20.
Zurück zum Zitat Ahmad T, Armuzzi A, Neville M, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens. 2003;62:527–35.CrossRefPubMed Ahmad T, Armuzzi A, Neville M, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens. 2003;62:527–35.CrossRefPubMed
21.
Zurück zum Zitat Lappalainen M, Halme L, Turunen U, et al. Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflamm Bowel Dis. 2008;14:1118–24.CrossRefPubMed Lappalainen M, Halme L, Turunen U, et al. Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflamm Bowel Dis. 2008;14:1118–24.CrossRefPubMed
22.
Zurück zum Zitat Annese V, Piepoli A, Latiano A, et al. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis Colon Rectum. 2005;48:57–64 (discussion 64-55).CrossRefPubMed Annese V, Piepoli A, Latiano A, et al. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis Colon Rectum. 2005;48:57–64 (discussion 64-55).CrossRefPubMed
23.
Zurück zum Zitat Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 2004;5:530–9.CrossRefPubMed Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 2004;5:530–9.CrossRefPubMed
24.
Zurück zum Zitat Daniel F, Loriot MA, Seksik P, et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007;13:19–23.CrossRefPubMed Daniel F, Loriot MA, Seksik P, et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007;13:19–23.CrossRefPubMed
25.
Zurück zum Zitat Ng SC, Tsoi KK, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:1164–76.CrossRefPubMed Ng SC, Tsoi KK, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:1164–76.CrossRefPubMed
26.
Zurück zum Zitat Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489–99.PubMedCentralCrossRefPubMed Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489–99.PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. Curr Gastroenterol Rep. 2014;16:416.CrossRefPubMed Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. Curr Gastroenterol Rep. 2014;16:416.CrossRefPubMed
28.
Zurück zum Zitat Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518–23.CrossRefPubMed Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518–23.CrossRefPubMed
29.
Zurück zum Zitat Rosenfeld G, Bressler B. The truth about cigarette smoking and the risk of inflammatory bowel disease. Am J Gastroenterol. 2012;107:1407–8.CrossRefPubMed Rosenfeld G, Bressler B. The truth about cigarette smoking and the risk of inflammatory bowel disease. Am J Gastroenterol. 2012;107:1407–8.CrossRefPubMed
30.
Zurück zum Zitat Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci. 2009;54:2456–62.CrossRefPubMed Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci. 2009;54:2456–62.CrossRefPubMed
31.
Zurück zum Zitat Hoie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-year disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102:1692–701.CrossRefPubMed Hoie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-year disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007;102:1692–701.CrossRefPubMed
32.
Zurück zum Zitat Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–90.CrossRefPubMed Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–90.CrossRefPubMed
33.
Zurück zum Zitat Weizman AV, Silverberg MS. Have genomic discoveries in inflammatory bowel disease translated into clinical progress? Curr Gastroenterol Rep. 2012;14:139–45.CrossRefPubMed Weizman AV, Silverberg MS. Have genomic discoveries in inflammatory bowel disease translated into clinical progress? Curr Gastroenterol Rep. 2012;14:139–45.CrossRefPubMed
34.
Zurück zum Zitat Charbonneau B, Wang AH, Maurer MJ, et al. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother. 2013;62:1475–84.PubMedCentralCrossRefPubMed Charbonneau B, Wang AH, Maurer MJ, et al. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother. 2013;62:1475–84.PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2:580–92.PubMed Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2:580–92.PubMed
36.
Zurück zum Zitat Canete JD, Suarez B, Hernandez MV, et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1547–52.CrossRefPubMed Canete JD, Suarez B, Hernandez MV, et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1547–52.CrossRefPubMed
37.
Zurück zum Zitat Montes A, Perez-Pampin E, Narvaez J, et al. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics. 2014;24:238–45.PubMed Montes A, Perez-Pampin E, Narvaez J, et al. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics. 2014;24:238–45.PubMed
38.
Zurück zum Zitat Libioulle C, Louis E, Hansoul S, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007;3:e58.PubMedCentralCrossRefPubMed Libioulle C, Louis E, Hansoul S, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007;3:e58.PubMedCentralCrossRefPubMed
Metadaten
Titel
Contribution of susceptibility variants at FCGR2A and 13q12 to the risk of relapse among Japanese patients with ulcerative colitis
verfasst von
Kouichi Asano
Motohiro Esaki
Junji Umeno
Atsushi Hirano
Yuji Maehata
Tomohiko Moriyama
Shotaro Nakamura
Takayuki Matsumoto
Takanari Kitazono
Publikationsdatum
01.11.2015
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 11/2015
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1062-3

Weitere Artikel der Ausgabe 11/2015

Journal of Gastroenterology 11/2015 Zur Ausgabe

Original Article—Liver, Pancreas, and Biliary Tract

Biphasic effect of alcohol intake on the development of fatty liver disease

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.